Healthcare Industry News:  Bavarian Nordic 

Biopharmaceuticals Personnel

 News Release - January 25, 2008

Bavarian Nordic A/S Announces Change in Management

KVISTGÅRD, Denmark, January 25 (HSMN NewsFeed) -- Bavarian Nordic announced today that Executive Vice President, Peter Wulff has chosen to seek new challenges outside Bavarian Nordic A/S. He will resign from his position at the end of July 2008 whereupon he will continue as consultant for the company.

Peter Wulff held the position as CEO and President of the company from its inception and until August 2007, where he took over the position as Head of Business Development. The company's success, from its inception and until the commercial breakthrough in 2007, where a large contract with the U.S. government was landed, can largely be attributed to Peter's efforts and contribution.

In future, business development will be an integrated part of the company's commercial organisation, headed by Nicolai Buhl Andersen.

CEO and President of Bavarian Nordic, Anders Hedegaard, said: "I would like to thank Peter for his contribution to Bavarian Nordic throughout the years. His work has been of great importance to Bavarian Nordic. We are pleased that he has offered his expertise and thorough knowledge about the international vaccine market to the company as a consultant going forward."

Asger Aamund
Chairman

About Bavarian Nordic

Bavarian Nordic (CSE: BAVA ) is a leading international biopharmaceutical company developing and producing innovative vaccines to prevent and treat infectious diseases and cancer. With operations in Denmark, Germany, the USA, and Singapore, Bavarian Nordic employs over 260 people. Bavarian Nordic's patented technology, MVA-BN®, is as been demonstrated in clinical studies, one of the world's safest, multivalent vaccine vectors for the development of vaccines against various infectious diseases such as smallpox, HIV/AIDS, as well as against breast and prostate cancer. Several MVA-BN®-based HIV and smallpox vaccines are in clinical Phase I and Phase II trials. Bavarian Nordic has ongoing development contracts with the US government to develop a third-generation smallpox vaccine, IMVAMUNE®. Bavarian Nordic has supplied several other governments with smallpox vaccines.

For more information please visit http://www.bavarian-nordic.com


Source: Bavarian Nordic

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.